About Us

Our team of world-class scientists and biotechnology leadership is devoted to discovering breakthrough medicines that change the standard of medical care for patients.

Sir Martin Evans, Nobel Laureate, and Ajan Reginald, former Global Head of Emerging Technologies at Roche, originally founded the company under the name Cell Therapy Ltd (CTL) in 2009. CTL was rebranded as Celixir in 2016.

News
Around the world, different countries - and entire continents -...
There are currently over 5,000 registered clinical trials testing regenerative...
The Impact of Cardiovascular Disease Cardiovascular disease (CVD) - in...
While regenerative medicine and tissue crafting are often cited in...
Presentations
Florence | 18 to 21 October 2016

Presentation by Celixir :

  • Fixing the So-called Unfixable: Regenerating Untreatable Fixed Myocardial Scar in Heart Failure Patients; A. Reginald, S. Sultan, L. Chapman, M. Evans, K, P. Antonitsis, S. Westaby and K. Anastasiadis

Celixir Posters :

  • Immunomodulatory Progenitor Cells: A Novel And Safe Allogeneic Therapy For Patients With Ischaemic Cardiomyopathy Undergoing Coronary Artery Bypass Grafting; S. Sultan, A. Reginald, L. Chapman, M. Evans, K, P. Antonitsis, S. Westaby and K. Anastasiadis
  • Tendoncel Phase II Placebo Controlled Randomized Clinical Trial Results For A Novel Allogeneic Regenerative Topical Medicine In Treatment Of Chronic Tendon Injury; A. Reginald, S. Sultan, A. Mousiadou, L. Chapman, M. Evans & G. Panagiotis
Events
Please see https://www.biofit-event.com/ for more information.
Lille / France 4 December 2018
Our Work in Pipeline
Heartcel (IMMUNOMODULATORY PROGENITOR [iMP] CELLS)
PHASE 2 : Our first investigational cardiac regenerative medicine consists...
Tendoncel (PLATELET LYSATE-BASED THERAPY)
PHASE 3 : Our investigational topical gel containing platelet lysate is...
Myocardion (PROGENITOR CELLS OF MESODERMAL LINEAGE [PML])
CLINICAL TRIAL READY : PML cells are being investigated as...
Find Out More
Our pivotal position in the rapidly evolving regenerative medicine field is supported by a group of leading investors.
Our continued focus on innovation is the key to unlocking the potential of regenerative medicine. We combine the unique expertise of scientists.
We are passionate about advancing ground-breaking regenerative medicines and work towards this goal via collaborative partnerships.
Twitter Feed